Vanguard Global Advisers
RIGL icon

Vanguard Global Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Vanguard Global Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949K Sell
24,265
-1,548
-6% -$47.7K ﹤0.01% 1775
2026
Q1 		$698K Buy
+25,813
New +$867K ﹤0.01% 1860

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's RIGL Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Rigel Pharmaceuticals (RIGL) stake by 6% in Q2 2026, selling an estimated $47.7K and leaving 24,265 shares worth $949K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Vanguard Global Advisers first reported a position in RIGL in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Vanguard Global Advisers held 24,265 shares of Rigel Pharmaceuticals worth $949K as of Q2 2026.
  • Vanguard Global Advisers sold 1,548 Rigel Pharmaceuticals shares in Q2 2026, an estimated $47.7K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1775 holding.
  • Vanguard Global Advisers first reported a position in Rigel Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.